Review Article | Published:

The endocannabinoid system and its therapeutic exploitation

Nature Reviews Drug Discovery volume 3, pages 771784 (2004) | Download Citation

Subjects

Abstract

The term 'endocannabinoid' — originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Δ9-tetrahydrocannabinol and their endogenous ligands — now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.

Key points

  • Cannabis has long been used for the relief of cramps and rheumatic pain, and in 1964 its main psychoactive ingredient — (−)-Δ9-tetrahydrocannabinol (THC) — was finally isolated and characterized.

  • The development by Pfizer of a non-classical cannabinoid led to the cloning of the first cannabinoid receptor, CB1, which was swiftly followed in 1993 by the cloning of the second receptor, CB2, and the isolation of endogenous ligands, the endocannabinoids, in 1992–1995.

  • Knowledge of the physiological function of the cannabinoid system is still emerging. However, the pathological alteration of cannabinoid signalling has been observed in psychiatric disorders; stroke; neurodegenerative conditions such as Parkinson's and Alzheimer's diseases; cancer; reproductive, cardiovascular and gastrointestinal disorders; and, perhaps most famously, in multiple sclerosis, making this signalling pathway a cornucopia of potential therapeutic targets.

  • Many of the enzymes involved in endocannabioid synthesis and degradation have now been characterized and are currently being pursued as therapeutic targets, including N-acylphosphatidylethanolamine-selective phospholipase D, fatty acid amide hydrolase, diacylglycerol lipase isozymes α and β, and monoacylglycerol lipase.

  • Other therapeutic strategies include small-molecule cannabinoid receptor agonists and antagonists, and the use of non-psychotropic plant cannabinoids. A CB1 receptor antagonist looks promising against obesity, metabolic syndrome and nicotine dependence after completing initial Phase III clinical trials. Clinical trials carried out so far with oral THC and plant cannabinoids for the treatment of multiple sclerosis and Parkinson's disease have shown some efficacy and few side effects.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585–1614 (1996).

  2. 2.

    in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.

  3. 3.

    & Cannabinoids in clinical practice. Drugs 60 1303–1314 (2000).

  4. 4.

    & Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647 (1964). The long-awaited conclusive chemical characterization of THC, the major psychoactive constituent of Cannabis.

  5. 5.

    , & Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137–143 (2003).

  6. 6.

    , , , & Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613 (1988). The first sound evidence for the existence of specific binding sites for THC.

  7. 7.

    , , , & Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).

  8. 8.

    & Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem. Phys. Lipids 121, 35–43 (2002).

  9. 9.

    , & Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65 (1993).

  10. 10.

    & Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot. Essent. Fatty Acids 53, 1–11 (1995).

  11. 11.

    et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992). The study reporting the identification of the first endocannabinoid, anandamide.

  12. 12.

    et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).

  13. 13.

    et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Commun. 215, 89–97 (1995).

  14. 14.

    & CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66, 161–171 (2002).

  15. 15.

    , , , & Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377–391 (2002).

  16. 16.

    The molecular logic of endocannabinoid signalling. Nature Rev. Neurosci. 4, 873–884 (2003).

  17. 17.

    , & The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141, 765–774 (2004).

  18. 18.

    Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129–180 (1997).

  19. 19.

    Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35, 607–634 (1995).

  20. 20.

    , , & Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521–528 (1998).

  21. 21.

    & Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565–572 (2001).

  22. 22.

    & Endocannabinoid signaling in the brain. Science 296, 678–682 (2002).

  23. 23.

    , & Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017–1066 (2003).

  24. 24.

    & Is cannabinoid transmission involved in rewarding properties of drugs of abuse? Br. J. Pharmacol. 136, 1083–1084 (2002).

  25. 25.

    , , & It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26, 184–192 (2003).

  26. 26.

    & Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2, 50–55 (2002).

  27. 27.

    , , & Cardiovascular effects of cannabinoids. Pharmacol. Ther. 95, 191–202 (2002).

  28. 28.

    & Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert. Opin. Investig. Drugs 12, 39–49 (2003).

  29. 29.

    , & Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch. Pharmacol. 368, 301–308 (2003).

  30. 30.

    & The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot. Essent. Fatty Acids 66, 301–307 (2002).

  31. 31.

    , & Cannabis, cannabinoids and reproduction. Prostaglandins Leukot. Essent. Fatty Acids 70, 189–197 (2004).

  32. 32.

    et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486–496 (2003).

  33. 33.

    , & Cannabinoids and cell fate. Pharmacol. Ther. 95, 175–184 (2002).

  34. 34.

    , , , & in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).

  35. 35.

    et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84–88 (2003). An important study, together with reference 37, exemplifying the 'on-demand' character of endocannabinoid-mediated protective functions.

  36. 36.

    , , & Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550–557 (2002).

  37. 37.

    et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530–534 (2002).

  38. 38.

    , , , & Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl Acad. Sci. USA 96, 12198–12203 (1999).

  39. 39.

    et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822–825 (2001). The first study pointing to a role for the endocannabinoids as orexigenic mediators.

  40. 40.

    et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423–431 (2003).

  41. 41.

    et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33, 2112–2114 (2002).

  42. 42.

    , , , & Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771–9775 (2002).

  43. 43.

    et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527–531 (2001).

  44. 44.

    , , , & Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432–1438 (2000).

  45. 45.

    et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018–1025 (2003).

  46. 46.

    et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300–302 (2001). The first example of the use of inhibitors of endocannabinoid inactivation as potential therapeutic agents.

  47. 47.

    et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84–87 (2000).

  48. 48.

    , & Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477, 219–225 (2003).

  49. 49.

    , , , & Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169, 400–406 (2001).

  50. 50.

    et al. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41, 195–202 (2001).

  51. 51.

    et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136–11141 (2003).

  52. 52.

    et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12, 2125–2129 (2001).

  53. 53.

    & Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705–713 (2000).

  54. 54.

    , & Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56, 523–527 (1993). The first report of the possible involvement of cannabinoid receptors in a neurodegenerative disorder.

  55. 55.

    et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908–914 (2003).

  56. 56.

    et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R345–R353 (2003).

  57. 57.

    , , , & CB1 cannabinoid receptor knockout in mice leads to leannes, resistence to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640–648 (2004).

  58. 58.

    et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518–521 (1997). Possibly the first example of a pathological condition involving an altered endocannabinoid system.

  59. 59.

    , , & Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035–1044 (1998).

  60. 60.

    et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Med. 7, 827–832 (2001).

  61. 61.

    et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38, 2048–2054 (2001).

  62. 62.

    et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563–570 (2001).

  63. 63.

    et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125, 765–774 (2003). A typical example of a protective role played 'on demand' by endocannabinoids in a peripheral organ.

  64. 64.

    et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J. 16, 1973–1975 (2002).

  65. 65.

    et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202–1209 (2004).

  66. 66.

    et al. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc. Natl Acad. Sci. USA 100, 14914–14919 (2003).

  67. 67.

    et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355, 1326–1329 (2000). The first human study pointing to the possible pathological consequences of over-active endocannabinoid signalling.

  68. 68.

    et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol. Hum. Reprod. 8, 188–195 (2002).

  69. 69.

    et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677–687 (2003).

  70. 70.

    , , , & Anandamide and other N-acylethanolamines in human tumors. Lipids 37, 907–912 (2002).

  71. 71.

    et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784–5789 (2001).

  72. 72.

    et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl Acad. Sci. USA 95, 8375–8380 (1998). The antiproliferative effects of the endocannabinoids against cancer cells in vitro were examined for the first time in this study. Together with reference 73, this marked the beginning of studies on the possible anticancer function of the endocannabinoid system.

  73. 73.

    et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. 6, 313–319 (2000).

  74. 74.

    et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745–2747 (2001).

  75. 75.

    et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43–50 (2003).

  76. 76.

    et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771–1773 (2003).

  77. 77.

    et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2 August 2004 (doi:10-1096/fj.04-1754fje).

  78. 78.

    et al. The peripheral cannabinoid receptor CB2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104, 526–534 (2004).

  79. 79.

    & Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 7, 469–475 (2003).

  80. 80.

    et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691 (1994). First proof that the endocannabinoid anandamide is an endogenous mediator in that it can be produced by neurons in an activity-dependent manner and inactivated by both neurons and astrocytes.

  81. 81.

    , & Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316, 977–984 (1996).

  82. 82.

    et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322, 671–677 (1997).

  83. 83.

    , & A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773–778 (1997).

  84. 84.

    , , & Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258, 9302–9306 (1983).

  85. 85.

    , , , & Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298–5305 (2004). Cloning of the major enzyme catalysing anandamide biosynthesis.

  86. 86.

    et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240, 53–62 (1996).

  87. 87.

    , & Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226–1242 (1997).

  88. 88.

    et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463–468 (2003). Reports the cloning of the first enzymes catalysing the biosynthesis of an endocannabinoid, 2-arachidonoylglycerol.

  89. 89.

    , & The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 160, 481–486 (2003).

  90. 90.

    , , & The endogenous cannabinoid system and brain development. Trends Neurosci. 23, 14–20 (2000).

  91. 91.

    , , & Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109, 319–327 (2004). An important study confirming conclusively that FAAH can be targeted for the development of new antihyperalgesic drugs.

  92. 92.

    , , & Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916–3923 (2003).

  93. 93.

    , , , & A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA 99, 8394–8399 (2002).

  94. 94.

    et al. Further evidence for the specific process for the membrane transport of anandamide. Biochem. J. 380, 265–272 (2004).

  95. 95.

    , , & Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69, 631–638 (1997).

  96. 96.

    et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094–1097 (1997).

  97. 97.

    , , , & Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272, 3315–3323 (1997).

  98. 98.

    , , , & Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298, 1793–1796 (2002).

  99. 99.

    et al. Evidence against the presence of an anandamide transporter. Proc. Natl Acad. Sci. USA 100, 4269–4274 (2003).

  100. 100.

    , , , & Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65, 1473–1481 (2003).

  101. 101.

    et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46, 1512–1522 (2003).

  102. 102.

    et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA (in the press).

  103. 103.

    & Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140, 802–808 (2003).

  104. 104.

    et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87 (1996). Reports the cloning of the first 'endocannabinoid enzyme', FAAH, a potential therapeutic target for analgesic and anxiolytic compounds.

  105. 105.

    et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371–9376 (2001).

  106. 106.

    et al. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294, 1209–1218 (2000).

  107. 107.

    et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med. 9, 76–81 (2003).

  108. 108.

    , , & Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nature Biotechnol. 21, 687–691 (2003).

  109. 109.

    , , , & cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 272, 27218–27223 (1997).

  110. 110.

    et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA 99, 10819–10824 (2002).

  111. 111.

    et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23–31 (1998).

  112. 112.

    et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA 96, 14228–14233 (1999).

  113. 113.

    et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl Acad. Sci. USA 100, 10529–10533 (2003).

  114. 114.

    et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627–634 (2002).

  115. 115.

    et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240–244 (1994). Describes the development of the first selective cannabinoid CB1-receptor antagonist, rimonabant, which is now in Phase III clinical trials being tested as an anti-obesity agent and against nicotine dependence.

  116. 116.

    et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123, 227–234 (2002).

  117. 117.

    et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121, 767–774 (2001).

  118. 118.

    Δ(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).

  119. 119.

    Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317–1324 (2004).

  120. 120.

    et al. The analgesic effect of oral Δ-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105, 79–88 (2003).

  121. 121.

    et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol. 406, 363–374 (2000).

  122. 122.

    et al. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. 281, 444–451 (2001).

  123. 123.

    et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. Eur. J. Pharmacol. 439, 83–92 (2002).

  124. 124.

    et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 262, 275–284 (1999).

  125. 125.

    et al. Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity. Pharmacology 66, 89–99 (2002).

  126. 126.

    et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126, 665–672 (1999).

  127. 127.

    et al. 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl 4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and anti-allodynic effects. J. Pharmacol. Exp. Ther. 310, 620–632 (2004).

  128. 128.

    in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).

  129. 129.

    , , , & A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17, 21–29 (2003).

  130. 130.

    Cannabis-based medicines — GW pharmaceuticals: high CBD, high THC, medicinal cannabis — GW pharmaceuticals, THC:CBD. Drugs RD 4, 306–309 (2003).

  131. 131.

    Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).

  132. 132.

    Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharm. Des. 6, 1339–1345 (2000).

  133. 133.

    et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50, 985–998 (2004).

  134. 134.

    et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852 (2001).

  135. 135.

    et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl Acad. Sci. USA 86, 9584–9587 (1989).

  136. 136.

    , , , & Activation and binding of peroxisome proliferator-activated receptor-γ by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63, 983–992 (2003).

  137. 137.

    , , , & (Solvay Pharmaceuticals) 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. WO0170700 (2001).

  138. 138.

    & (Univ. Connecticut) Cannabimimetic indole derivatives. WO0128557 (2001).

  139. 139.

    & (Univ. Connecticut) Retro-anandamides, high affinity and stability cannabinoid receptor ligands. WO0128498 (2001).

  140. 140.

    et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 9, 343–358 (2003).

  141. 141.

    et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644–650 (1998).

  142. 142.

    , , , & In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther. 296, 420–425 (2001).

  143. 143.

    et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol. 129, 1577–1584 (2000).

  144. 144.

    et al. UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362, 1517–1526 (2003). The first very large controlled clinical study with THC and Cannabis extract as potential treatments for a human disorder.

  145. 145.

    et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64, 459–465 (2003).

  146. 146.

    et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108–2111 (2001).

  147. 147.

    , , , & Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17, 145–149 (2002).

  148. 148.

    , , & The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13, 409–412 (2001).

  149. 149.

    et al. Lack of analgesic efficacy of oral Δ-9-tetrahydrocannabinol in postoperative pain. Pain 106, 169–172 (2003).

  150. 150.

    et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139, 258–266 (2003).

  151. 151.

    , , , & Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J. Int. Neuropsychol. Soc. 9, 679–689 (2003).

  152. 152.

    Marijuana safety study completed: weight gain, no safety problems. AIDS Treat. News 348, 3–4 (2000).

  153. 153.

    et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323, 16–21 (2001).

  154. 154.

    et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290, 1757–1762 (2003).

  155. 155.

    et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30, 548–554 (2002).

  156. 156.

    et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258–267 (1999).

  157. 157.

    & Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461–472 (2003). The first study pointing to a possible functional difference between 2-AG and anandamide in the modulation of synaptic neurotransmission.

  158. 158.

    , & Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481–496 (2003).

  159. 159.

    et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl Acad. Sci. USA 98, 3662–3665 (2001).

  160. 160.

    et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020–1024 (2002).

  161. 161.

    et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA 99, 8400–8405 (2002).

  162. 162.

    , & Discovery and characterization of endogenous cannabinoids. Life Sci. 65, 573–595 (1999).

  163. 163.

    et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 248, 515–522 (1998).

Download references

Acknowledgements

The work of the authors is currently supported by grants from the Ministry of Italian University and Research (MIUR, Fondo Italiano per la Ricerca di Base, to V.D.M.), the Volkswagen Stiftung (to V.D.M.), GW Pharm Ltd (to V.D.M., M.B. and L.D.P.), the Associazione Italiana per la Ricerca sul Cancro (AIRC, to M.B.) and the Associazione ERMES (to M.B.).

Author information

Affiliations

  1. Endocannabinoid Research Group, Institutes of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Napoli, Italy.

    • Vincenzo Di Marzo
  2. Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno, via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy.

    • Luciano De Petrocellis
  3. Endocannabinoid Research Group, Institutes of Cybernetics, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Napoli, Italy.

    • Maurizio Bifulco

Authors

  1. Search for Vincenzo Di Marzo in:

  2. Search for Maurizio Bifulco in:

  3. Search for Luciano De Petrocellis in:

Competing interests

V.D.M, M.B. and L.D.P. receive research funding from G. W. Pharm and Sanofi-Synthelabo.

Corresponding author

Correspondence to Vincenzo Di Marzo.

Glossary

Δ9-TETRAHYDROCANNABINOL

(THC). The major psychotropic component of Cannabis sativa, and one of about 66 'cannabinoids' found in the flowers of this plant.

CANNABINOIDS

Natural lipophilic products from the flower of Cannabis sativa, most of which have a typical bi-cyclic or tri-cyclic structure and a common biogenetic origin from olivetol.

CANNABINOID RECEPTORS

G-protein-coupled receptors for THC, so far identified in most vertebrate phyla. Two subtypes are known: CB1 and CB2.

ENDOCANNABINOIDS

Endogenous agonists of cannabinoid receptors in animal organisms.

ANANDAMIDE

One of the most studied endocannabinoids, named from the Sanskrit word 'ananda' for 'bliss'.

NEUROMODULATORY

A physiological action consisting of the capability of modulating neurotransmitter release and/or action.

ENDOCANNABINOID MEMBRANE TRANSPORTER(S)

Putative and elusive membrane protein(s) that has (have) been postulated to be capable of binding selectively to the endocannabinoids and to facilitate their transport across the plasma membrane according to concentration gradients.

ANALYTICAL TECHNIQUES FOR ENDOCANNABINOID STUDIES

Methodologies for quantifying the levels of the endocannabinoids and of cannabinoid receptors, consisting mostly of isotope-dilution mass-spectrometric techniques for anandamide and 2-AG, polymerase chain reaction and in situ hybridization techniques for receptor and enzyme mRNAs, western immunoblotting and immunohistochemistry for receptor and enzyme proteins.

'ON DEMAND'

A typical property of the production of endocannabinoids, which are made in the organism only 'when and where needed'.

NON-PSYCHOTROPIC CANNABINOID

Any plant or synthetic cannabinoid-like compound that does not induce, in animal models and in humans, the central cannabimimetic effects typical of THC.

PARTIAL AGONIST

Any receptor agonist that does not induce a full functional response in a given functional assay of receptor activation.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd1495

Further reading